BioSpace News Archive

DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months and year ended December 31, 2022 and provided a corporate update.

BioMarin Pharmaceutical Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental New Drug Application (sNDA) for VOXZOGO® (vosoritide) for injection to expand treatment in the United States to include children with achondroplasia under the age of 5.

Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E81) (“APC” or the “Company”) is pleased to announce that all conditions have been satisfied or waived and the Board of Directors of the Company has authorized the Company to complete its plan of arrangement under the Business Corporations Act (British Columbia) (the “Arrangement”)

Economic activity in the hospital subsector grew in February for the 33rd consecutive month, say the nation’s hospital supply executives in the latest Hospital ISM® Report On Business®.

INITIO Medical Group is the first private nuclear medicine facility in Canada to be awarded a therapeutic license to administer Lutetium-177-PSMA (prostate specific membrane antigen) for the treatment of advanced prostate cancer, specifically “metastatic castration resistant prostate cancer” also known as “mCRPC”.

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the fourth quarter and full year ended December 31, 2022.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Eli Kalif, EVP and Chief Financial Officer will present at the Barclays Global Healthcare Conference on Tuesday, March 14, 2023. The presentation will begin at 10:15 A.M. Eastern Time.

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company announced full year 2022 financial results and provided a Company update.

Nuvo Pharmaceuticals Inc. d/b/a Miravo Healthcare is pleased to announce that, its shareholders voted in favour of a special resolution to approve the previously announced plan of arrangementpursuant to which, among other things, Searchlight Pharma Inc. will acquire all of the Company shares.

Covis Pharma Group, announced it has submitted a response to the Presiding Officer’s report summarizing the October 17-19, 2022 public hearing and providing recommendations on the Center for Drug Evaluation and Research’s proposal to withdrawal approval for Makena®, the only FDA-approved treatment to reduce the risk of preterm birth in pregnant women who have had a prior spontaneous preterm birth.